FRC-303 is a CHD1 inhibitor with a Kd of 0.14 µM and an IC50 of 0.18 µM. FRC-303 binds to the H3K4me3 binding site of CHD1 tandem chromodomain, forms aromatic cage interactions and extended ligand contacts, acts as a methyl-lysine mimic, and occupies natural peptide ligand-binding regions. FRC-303 can be used for the research of prostate cancer[1].
Molecular Weight:
704.90
Formula:
C41H52N8O3
Target:
DNA/RNA Synthesis
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
